Catalog No.
PHF09601
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human AQP4/Aquaporin-4.
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Aquaporin-4, AQP-4, Mercurial-insensitive water channel, MIWC, WCH4, AQP4
Purification
Purified by antigen affinity column.
Accession
P55087
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders., PMID:40506618
Relapsing anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder diagnosed double positive for anti-myelin oligodendrocyte glycoprotein antibody., PMID:40506104
Oligodendroglia in Neuromyelitis Optica Spectrum Disorder., PMID:40500507
The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGAD., PMID:40495001
Factors for Rituximab Refractoriness in AQP4-IgG+ NMOSD: A Cohort Study., PMID:40492601
Rituximab as First-Line Compared to Escalation Immunotherapy Is Associated With Lower Disability Accumulation in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Multicenter Cohort Study From Germany and the United Kingdom., PMID:40492480
Dual BLyS/APRIL targeted therapy with telitacicept in rituximab-refractory SLE-associated neuromyelitis optica spectrum disorder: a case report., PMID:40491913
Neuromyelitis optica in a young male patient: a case report and literature review., PMID:40486546
Comorbidities Are Associated With Unfavorable Outcome in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Exploratory Study From the CROCTINO Cohort., PMID:40485599
Tumefactive demyelination as the first presentation of MOG ab-associated disease., PMID:40479755
A Differential Proteomic Analysis on Patient Sera with Neuromyelitis Spectrum Disorders (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) Suggested Shared and Distinct Disease Mechanisms., PMID:40464632
Translational insights from EAE models : decoding MOGAD pathogenesis and therapeutic innovation., PMID:40463369
Nausea, Vertical Gaze Palsy, and Excessive Sleep: An Unusual Presentation of Pediatric AQP4-Antibody Positive Neuromyelitis Optica Spectrum Disorder., PMID:40456289
From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis., PMID:40447786
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study., PMID:40442445
The role of IL-39 in autoimmune diseases: From general to immunopathogenesis., PMID:40440970
Early neuromyelitis optica antibody-induced molecular changes in aquaporin 4 and associated proteins at astrocyte endfeet in murine brain tissues., PMID:40436483
A Case Report of Neuromyelitis Optica Spectrum Disorder in a Young Patient With Systemic Lupus Erythematosus., PMID:40432657
AQP-4 autoantibodies as potential early diagnostic biomarkers for NEC., PMID:40424658
Anti-IL-6R antibody treatment changes microglial phenotype in AQP4 peptide-immunized mice, leading to suppression of myelitis severity., PMID:40403514
Aggressive and Refractory Attack of AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder Treated With Ravulizumab: A Case Report., PMID:40400837
Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis optica spectrum disorder., PMID:40380029
Intravenous immunoglobulin for the acute treatment of refractory optic neuritis in Japan., PMID:40377800
Detrimental Roles of Innate Immune cells in Neuromyelitis Optica Spectrum Disorder: Pathogenesis and Therapeutic Targeting., PMID:40377013
Reply to Letter: Real-World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell-Based Assay., PMID:40368601
Letter to: Real-World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell-Based Assay., PMID:40368592
Anti-IL-6 receptor antibody suppresses onset of paralytic symptoms in AQP4 peptide-immunized mice without lowering bone strength or mineral density., PMID:40359583
Seronegative Autoimmune Encephalomyelitis with Area Postrema Symptoms., PMID:40336575
CD4-Positive T-Cell Responses to MOG Peptides in MOG Antibody-Associated Disease., PMID:40332104
Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease., PMID:40324120
Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies., PMID:40317881
Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)., PMID:40292288
Assessing fall risk in multiple sclerosis using patient-reported outcomes and wearable gait metrics., PMID:40292035
Advances in the treatment of neuromyelitis optic spectrum disorder., PMID:40291752
Clinical characteristics and outcome of double-AQP4/MOG-seronegative and not MS-associated monophasic and relapsing demyelinating transverse myelitis: A monocenter study., PMID:40288332
The association between information processing speed and clinical features in people with multiple sclerosis and neuromyelitis optica: a comparative study., PMID:40278979
Immune-related biomarkers in the neuromyelitis optica spectrum disorder; pathogenesis and therapeutic approaches., PMID:40274184
Very late-onset neuromyelitis optica, a report of two cases., PMID:40245981
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study., PMID:40227344
Comparison of clinical features of aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein associated disorder (MOGAD), and double seronegative NMOSD - A single center experience., PMID:40220551
Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: A six-month interim analysis of a multicenter medical chart review., PMID:40203604
Epidemiology of aquaporin-4 seropositive neuromyelitis optica spectrum disorder in the Alicante health area, Spain: A population-based study., PMID:40203603
Intractable Vomiting and Hiccups: An Atypical Presentation of Neuromyelitis Optica Spectrum Disorder., PMID:40200627
Telitacicept: A New Therapy for the Treatment of Optic Neuromyelitis Spectrum Disease Associated with Other Autoimmune Disorders., PMID:40196354
Satralizumab after inebilizumab treatment in a patient with recurrent neuromyelitis optica spectrum disorder: A case report., PMID:40193676
Ethnic and racial differences in MOG antibodies findings in seronegative NMOSD patients: Insights from Buenos Aires, Argentina., PMID:40188628
Concomitant Sjögren's disease in patients with NMOSD: impacts on neurologic disease severity and recurrence., PMID:40188346
Comparison of the clinical and laboratory characteristics of neuromyelitis optica spectrum disorder with or without cerebrospinal fluid oligoclonal bands: a cohort with 36-month follow-up., PMID:40160821
Comparison of vision-related quality of life in NMOSD and MOGAD., PMID:40157039
The immunological processes behind aquaporin 4-antibody seropositive neuromyelitis optica spectrum disorders., PMID:40154151
For research use only. Not for human or drug use.
